1. Counterproductive effects of Daratumumab and checkpoint inhibitor for the treatment of patients with relapsing NK/T lymphoma
- Author
-
Tang Tp, Choon Kiat O, Rotzschke O, Tan D, Liangwei W, Kia Joo P, Kim Peng T, Jinquan L, Wei Lin Lee, and Ser Mei K
- Subjects
Combination therapy ,Downregulation and upregulation ,business.industry ,Cancer research ,Antibody titer ,Medicine ,T-cell lymphoma ,Daratumumab ,CD38 ,business ,medicine.disease ,Malignancy ,Lymphoma - Abstract
Natural killer/T cell lymphoma (NK/T L) is an aggressive malignancy associated with poor prognosis in relapsed patients. Although L-asparaginase based treatments are recommended as first-line treatment in relapsed patients, advances in immunotherapies such as checkpoint inhibitions have provided new therapeutic alternatives. However, as clinical outcomes for checkpoint inhibitors seemed to vary between NK/T L patients, combination therapies have been suggested to improve treatment efficacy. Here, we compared the effects of Daratumumab (anti-CD38)/anti-PD-1 combination therapy versus anti-PD-1 monotherapy on two relapsed NK/T L patients. Anti-PD-1 triggered an upregulation of CD38 on activated T cells, leading to depletion by Daratumumab. Concomittantly, EBV-specific antibody titer was also reduced alongside with depletion of CD38+ B cells and antibody-producing plasmablasts. Taken together, combining anti-CD38 and anti-PD-1 is likely to be antithetic.
- Published
- 2021